NorthWest Biotherapeutics Inc (NWBO)

[Single Stock]

$2bn - Founded June 2021 pre revenue :
Johnson & Johnson Reiterate buy
Ambrx Biopharma Cayman
By Bloomberg Automation
(Bloomberg) -- Johnson & Johnson to Buy Ambrx Biopharma Cayman, according to a press release.
Key excerpts:
Johnson & Johnson announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates, in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired.
The closing of the transaction is expected to occur in the first half of 2024, subject to receipt of Ambrx shareholder approval, as well as clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
To view the source of this information, click here